We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Treatments for Inflammatory Diseases Sought by Singapore's CREATE Program

By LabMedica International staff writers
Posted on 06 Jul 2010
Internationally renowned top-ranked investigators in the biological sciences and other areas will be cooperating in Singapore's National Research Foundation's CREATE research (Campus for Research Excellence and Technological Enterprise) program.

CREATE has been designed to be a talent magnet and innovation hub. More...
The research centers in CREATE will host professors, research investigators, doctoral, and postdoctoral researchers who will form research groups to pursue research programs in areas that are aligned both to Singapore's strategic interest and those of the respective institutions. CREATE entities will have intensive collaboration with Singapore-based universities, polytechnics, laboratories, and research institutes, in cutting-edge research projects and in the attraction of global talent.

A recently announced participant in the CREATE program is the Hebrew University of Jerusalem (Israel). The Hebrew University's research project will focus on cellular and molecular mechanisms of inflammation. The objective of the project is to accelerate the development of diagnostic/prognostic indicators and novel therapeutics for common inflammatory diseases in Asia and elsewhere.

"This collaborative research program will leverage on the existing strengths
of both Hebrew University and National University of Singapore. We see great strategic value in this research, given the increasing prevalence of inflammatory diseases throughout the region. We expect our work to lead to scientific breakthroughs in understanding and developing therapies for inflammatory diseases,” said Dr. Ehud Razin professor of cancer research at the Hebrew University of Jerusalem.

Dr. Tan Chorh Chuan, president of the National University of Singapore, said, "Discovery and evaluation of new treatments for inflammatory diseases continue to be of critical importance. We are pleased to partner with the Hebrew University of Jerusalem under the CREATE program. With strong commitment from both sides, we are confident that this collaboration will have a major impact by addressing important research and medical needs, both in the region and the world.”

Related Links:
Singapore's National Research Foundation's
Hebrew University of Jerusalem
National University of Singapore



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.